Profile data is unavailable for this security.
About the company
Galecto, Inc. is a clinical-stage biotechnology company. The Company is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Company’s initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). It is developing GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate also includes GB1211, a selective oral small molecule inhibitor of galectin-three, is chemically distinct from GB0139 and is being developed for the treatment of various oncology indications and liver cirrhosis, and GB2064 is a selective oral small molecule inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow.
- Revenue in USD (TTM)0.00
- Net income in USD-25.43m
- Incorporated2019
- Employees13.00
- LocationGalecto Inc75 State Street, Suite 100BOSTON 02109United StatesUSA
- Fax+1 (302) 655-5049
- Websitehttps://galecto.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GlucoTrack Inc | 0.00 | -12.05m | 16.00m | 6.00 | -- | -- | -- | -- | -2.42 | -2.42 | 0.00 | -0.6004 | 0.00 | -- | -- | 0.00 | -251.32 | -94.01 | -493.89 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | -- | -- | -- | -- | -60.02 | -- | -- | -- |
| Ibio Inc | 50.00k | -17.13m | 16.39m | 26.00 | -- | 0.6509 | -- | 327.70 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
| AIM ImmunoTech Inc | 201.00k | -28.05m | 16.63m | 26.00 | -- | 2.72 | -- | 82.72 | -0.5703 | -0.5703 | 0.004 | 0.1068 | 0.0082 | -- | 12.18 | 7,730.77 | -113.70 | -45.64 | -149.16 | -48.35 | 71.14 | -231.75 | -13,952.74 | -11,695.01 | -- | -- | 0.3018 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| Cell Source Inc | 0.00 | -6.45m | 16.78m | -- | -- | -- | -- | -- | -0.1627 | -0.1627 | 0.00 | -0.413 | 0.00 | -- | -- | -- | -1,300.91 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -5.14 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| OpGen Inc | 1.96m | -22.39m | 16.88m | 100.00 | -- | -- | -- | 8.59 | -20.01 | -20.01 | 1.66 | -8.65 | 0.1553 | -- | 6.09 | -- | -176.99 | -87.95 | -15,455.17 | -127.65 | 3.15 | 15.42 | -1,139.66 | -794.78 | -- | -20.25 | -- | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
| Synlogic Inc | 3.17m | -56.16m | 17.08m | 6.00 | -- | 1.07 | -- | 5.39 | -7.24 | -7.24 | 0.3549 | 1.37 | 0.0628 | -- | -- | 528,333.30 | -111.31 | -40.57 | -131.17 | -43.82 | -- | -- | -1,771.74 | -3,245.93 | -- | -- | 0.00 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
| Mira Pharmaceuticals Inc | 0.00 | -12.78m | 17.15m | 3.00 | -- | 7.73 | -- | -- | -0.8562 | -0.8562 | 0.00 | 0.1501 | 0.00 | -- | -- | 0.00 | -373.77 | -- | -737.47 | -- | -- | -- | -- | -- | -- | -3.17 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
| Galecto Inc | 0.00 | -25.43m | 17.23m | 13.00 | -- | 0.6347 | -- | -- | -23.45 | -23.45 | 0.00 | 21.74 | 0.00 | -- | -- | 0.00 | -59.06 | -48.46 | -75.34 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
| BioVie Inc | 0.00 | -37.18m | 17.31m | 18.00 | -- | 0.9117 | -- | -- | -9.63 | -9.63 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -94.32 | -456.35 | -149.75 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.2969 | -- | -- | -- | -92.67 | -- | -- | -- |
| Evaxion Biotech A/S - ADR | 278.00k | -15.21m | 17.56m | 49.00 | -- | 13.60 | -- | 63.18 | -36.98 | -36.98 | 0.1048 | 0.2316 | 0.0174 | -- | 0.3493 | 5,673.47 | -95.08 | -100.11 | -126.11 | -131.65 | -- | -- | -5,469.42 | -131,560.30 | -- | -- | 0.8933 | -- | -- | -- | 4.51 | -- | 65.53 | -- |
| NRX Pharmaceuticals Inc | 0.00 | -24.83m | 17.63m | 2.00 | -- | -- | -- | -- | -1.62 | -1.62 | 0.00 | -1.70 | 0.00 | -- | -- | -- | -197.97 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -189.12 | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Bioxytran Inc | 0.00 | -3.51m | 17.74m | 2.00 | -- | -- | -- | -- | -0.023 | -0.023 | 0.00 | -0.0023 | 0.00 | -- | -- | -- | -2,635.88 | -1,420.53 | -- | -- | -- | -- | -- | -- | -- | -20.68 | -- | -- | -- | -- | -73.71 | -- | -- | -- |
| Athira Pharma Inc | 0.00 | -113.45m | 17.87m | 65.00 | -- | 0.2144 | -- | -- | -2.97 | -2.97 | 0.00 | 2.17 | 0.00 | -- | -- | 0.00 | -71.06 | -30.73 | -83.81 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Cocrystal Pharma Inc | 0.00 | -17.93m | 17.91m | 12.00 | -- | 1.03 | -- | -- | -1.76 | -1.76 | 0.00 | 1.71 | 0.00 | -- | -- | 0.00 | -61.98 | -50.94 | -66.88 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
| Lyra Therapeutics Inc | 1.82m | -101.39m | 18.39m | 87.00 | -- | 0.5938 | -- | 10.11 | -1.61 | -1.61 | 0.0294 | 0.4733 | 0.0165 | -- | -- | 20,681.82 | -92.07 | -58.01 | -108.51 | -68.69 | -- | -- | -5,570.88 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
Data as of Sep 19 2024. Currency figures normalised to Galecto Inc's reporting currency: US Dollar USD
5.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 30 Jun 2024 | 23.17k | 2.14% |
| Geode Capital Management LLCas of 30 Jun 2024 | 8.57k | 0.79% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 8.51k | 0.78% |
| G1 Execution Services LLCas of 30 Jun 2024 | 6.73k | 0.62% |
| Citadel Securities LLCas of 30 Jun 2024 | 5.14k | 0.47% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.80k | 0.17% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 1.43k | 0.13% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 30 Jun 2024 | 1.22k | 0.11% |
| Two Sigma Securities LLCas of 30 Jun 2024 | 1.09k | 0.10% |
| Summit Trail Advisors LLCas of 30 Jun 2024 | 1.00k | 0.09% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
